Sihuan Pharmaceutical Holdings Group (HK:0460) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sihuan Pharmaceutical Holdings Group Ltd. has announced that their subsidiary, Huisheng Biopharmaceutical, received NMPA approval for Insulin Degludec Injection, the first domestic biosimilar of the original diabetes drug Tresiba® in China. This approval marks a significant addition to the company’s diabetes care portfolio, offering a cost-effective and flexible glucose control option for the large and growing diabetic population in China. The move is expected to drive future business growth for the Group and its subsidiary, Huisheng Biopharmaceutical, which specializes in diabetes and complications.
For further insights into HK:0460 stock, check out TipRanks’ Stock Analysis page.
